5-Azacytidine: a new active agent for the treatment of acute leukemia.

Suppr

超能文献

作者信息

Karon M, Sieger L, Leimbrock S, Finklestein J Z, Nesbit M E, Swaney J J

出版信息

Blood. 1973 Sep;42(3):359-65.

PMID:4125239

Abstract

摘要

相似文献

5-Azacytidine: a new active agent for the treatment of acute leukemia.

Blood. 1973 Sep;42(3):359-65.

Treatment of acute leukemia with 5-azacytidine (NSC-102816).用5-氮杂胞苷（NSC-102816）治疗急性白血病。

Cancer Chemother Rep. 1973 Sep-Oct;57(3):319-23.

6-Azauridine in combination chemotherapy of childhood acute myelocytic leukemia.6-氮杂尿苷用于儿童急性髓细胞白血病的联合化疗

Cancer. 1972 Apr;29(4):1057-60. doi: 10.1002/1097-0142(197204)29:4<1057::aid-cncr2820290455>3.0.co;2-q.

Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer.

Cancer Chemother Rep. 1972 Oct;56(5):649-52.

Continuous infusion of 5-azacytidine as induction for acute nonlymphocytic leukemia in patients with previous exposure to 5-azacytidine.对于既往接触过5-氮杂胞苷的患者，持续输注5-氮杂胞苷作为急性非淋巴细胞白血病的诱导治疗。

Oncology. 1983;40(3):192-4. doi: 10.1159/000225723.

5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia.5-氮杂胞苷（NSC 102816）：一种治疗粒细胞性白血病的新药。

Blood. 1976 Sep;48(3):331-7.

5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.5-氮杂胞苷。一种对急性髓性白血病有效的新型抗癌药物。

Ann Intern Med. 1976 Aug;85(2):237-45. doi: 10.7326/0003-4819-85-2-237.

5-azacytidine in acute leukemia.急性白血病中的5-氮杂胞苷

Cancer. 1978 Nov;42(5):2111-4. doi: 10.1002/1097-0142(197811)42:5<2111::aid-cncr2820420505>3.0.co;2-i.

Pomp combination chemotherapy of adult acute leukemia.

Cancer. 1973 Jul;32(1):69-75. doi: 10.1002/1097-0142(197307)32:1<69::aid-cncr2820320109>3.0.co;2-0.

5-azacytidine in childhood leukemia.

Neoplasma. 1971;18(5):493-503.

引用本文的文献

New perspectives on DNA methylation modifications in ocular diseases.眼部疾病中DNA甲基化修饰的新视角。

Int J Ophthalmol. 2025 Feb 18;18(2):340-350. doi: 10.18240/ijo.2025.02.19. eCollection 2025.

Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia.急性髓系白血病移植后维持治疗的新机制

Front Oncol. 2022 Jul 12;12:892289. doi: 10.3389/fonc.2022.892289. eCollection 2022.

6, -Diaryl-1,3,5-triazine-2,4-diamines: synthesis, antiproliferative activity and 3D-QSAR modeling.6, -二芳基-1,3,5-三嗪-2,4-二胺：合成、抗增殖活性及三维定量构效关系建模

RSC Adv. 2020 Mar 25;10(21):12135-12144. doi: 10.1039/d0ra00643b. eCollection 2020 Mar 24.

Advances in Therapeutic -Nucleosides and -Nucleic Acids with Unusual Handedness.手性治疗性核苷和核酸的研究进展。

Genes (Basel). 2021 Dec 24;13(1):46. doi: 10.3390/genes13010046.

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia.急性髓系白血病对维奈托克和去甲基化药物的耐药性。

Cancer Drug Resist. 2021;4(1):125-142. doi: 10.20517/cdr.2020.95. Epub 2021 Mar 19.

Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update.人类癌症中肿瘤抑制基因编码和非编码基因的表观遗传失活：更新。

Open Biol. 2017 Sep;7(9). doi: 10.1098/rsob.170152.

Enhanced Anti-Tumor Activity of 5-Azacytidine by Entrapment into Solid Lipid Nanoparticles.通过包封于固体脂质纳米粒增强5-氮杂胞苷的抗肿瘤活性

Adv Pharm Bull. 2016 Sep;6(3):367-375. doi: 10.15171/apb.2016.048. Epub 2016 Sep 25.

Epigenetic therapies in MDS and AML.骨髓增生异常综合征和急性髓系白血病的表观遗传学治疗。

Adv Exp Med Biol. 2013;754:253-83. doi: 10.1007/978-1-4419-9967-2_13.

Epigenomics in cancer management.癌症管理中的表观基因组学。

Cancer Manag Res. 2010 Oct 27;2:255-65. doi: 10.2147/CMR.S7280.

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine.表观遗传学方法在骨髓增生异常综合征治疗中的应用：阿扎胞苷的临床效用。

Onco Targets Ther. 2010 Sep 7;3:157-65. doi: 10.2147/ott.s5852.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验